
ERYTECH Pharma S.A. ERYP
Annual report 2022
added 12-21-2024
ERYTECH Pharma S.A. Total Assets 2011-2026 | ERYP
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets ERYTECH Pharma S.A.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.8 M | 66.8 M | 80.4 M | 119 M | 168 M | 195 M | 45 M | 53 M | 40.6 M | 17.9 M | 10.1 M | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 10.1 M | 76.5 M |
Quarterly Total Assets ERYTECH Pharma S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 66.8 M | - | 83.8 M | - | 80.4 M | - | 89.1 M | - | 119 M | - | 146 M | - | 168 M | - | - | - | 195 M | - | - | - | 45 M | - | - | - | 53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 45 M | 105 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.35 | -2.88 % | $ 359 M | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.65 | 1.3 % | $ 8.78 B | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
124 M | $ 2.57 | -3.57 % | $ 16.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
22 B | $ 88.14 | -3.44 % | $ 27.2 B | ||
|
Coherus BioSciences
CHRS
|
258 M | $ 1.61 | -3.89 % | $ 189 M | ||
|
Akari Therapeutics, Plc
AKTX
|
47.9 M | $ 3.52 | -0.56 % | $ 237 B | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 314.88 | -4.68 % | $ 41.3 B | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | ||
|
Burford Capital Limited
BUR
|
3.11 B | $ 4.42 | -1.12 % | $ 730 M | ||
|
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
argenx SE
ARGX
|
8.68 B | $ 752.58 | 0.58 % | $ 25 B | ||
|
Завод ДИОД
DIOD
|
1.4 B | - | - | - | ||
|
Фармсинтез
LIFE
|
2.05 B | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Aptorum Group Limited
APM
|
16.1 M | $ 0.91 | 2.52 % | $ 4.96 M | ||
|
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Teligent, Inc.
TLGT
|
87.8 M | - | -13.85 % | $ 16.1 M | ||
|
Cerus Corporation
CERS
|
222 M | $ 1.84 | -0.81 % | $ 351 M | ||
|
AbbVie
ABBV
|
134 B | $ 202.58 | -1.96 % | $ 358 B | ||
|
Aquestive Therapeutics
AQST
|
160 M | $ 4.03 | -1.59 % | $ 431 M | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
Viela Bio, Inc.
VIE
|
423 M | - | - | $ 2.91 B | ||
|
AbCellera Biologics
ABCL
|
1.36 B | $ 3.31 | -2.36 % | $ 989 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
271 M | $ 8.15 | -0.85 % | $ 223 M |